PremiumThe FlyKoru Medical reports Q4 EPS (13c), consensus (2c) Koru Medical reports Q4 EPS (13c), consensus (2c) Koru Medical sees FY25 revenue $38M-$39M, consensus $38.4M PremiumThe FlyKoru announces pact for next-gen subcutaneous immunoglobulin infusion system Koru Medical announces Phase 3 trial collaboration for new drug indication Koru Medical price target raised to $6 from $5 at Craig-Hallum PremiumThe FlyKoru Medical price target raised to $5 from $4 at Craig-Hallum Koru Medical price target raised to $4 from $3 at Canaccord KORU Medical Systems Reports Strong Q3 Growth